The City Hospital Association
The City Hospital Association was paid $16.46M by Medicaid between Jan 2018 and Dec 2024, across 216 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
EAST LIVERPOOL, OH 43920
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,284 | $1.68M | |
| 2019 | 54,076 | $1.36M | |
| 2020 | 46,795 | $1.92M | |
| 2021 | 55,830 | $1.92M | |
| 2022 | 60,981 | $1.98M | |
| 2023 | 121,784 | $4.14M | |
| 2024incomplete | 100,993 | $3.46M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 23,658 | 21,897 | $2.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 22,657 | 20,808 | $2.73M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 14,858 | 13,346 | $2.05M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.5% | 3,232 | 2,746 | $1.07M |
| 80053 | Comprehensive metabolic panel | 4.9% | 48,257 | 39,275 | $802K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.7% | 5,788 | 5,292 | $777K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 9,024 | 2,253 | $580K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.3% | 6,677 | 2,062 | $538K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.9% | 5,688 | 1,654 | $482K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,330 | 1,181 | $356K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,089 | 952 | $309K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 48,407 | 38,400 | $286K |
204 more codes
| 41899 | Unlisted procedure, dentoalveolar structures | 1.4% | 200 | $236K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 6,256 | $181K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 8,774 | $171K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 555 | $164K |
| 80061 | Lipid panel | <1% | 10,395 | $144K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,181 | $142K |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,554 | $136K |
| 82607 | <1% | 3,914 | $104K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,964 | $101K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 760 | $95K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,425 | $90K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 705 | $86K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,221 | $82K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 582 | $74K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 526 | $73K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,871 | $70K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 526 | $63K |
| 81001 | <1% | 16,799 | $59K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,068 | $53K |
| 97161 | <1% | 561 | $50K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 192 | $50K |
| 85027 | <1% | 4,736 | $49K | |
| 82728 | <1% | 2,051 | $48K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,634 | $42K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 297 | $40K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 801 | $40K |
| 84439 | <1% | 1,882 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,395 | $38K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,866 | $38K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,293 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,603 | $29K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 14 | $26K |
| 87070 | <1% | 1,221 | $26K | |
| 87088 | <1% | 7,878 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,755 | $24K |
| 97164 | <1% | 432 | $24K | |
| 83605 | <1% | 6,150 | $24K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,462 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,425 | $22K |
| 83550 | <1% | 1,923 | $21K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 890 | $21K |
| 84484 | <1% | 4,972 | $20K | |
| 82977 | <1% | 1,344 | $20K | |
| 82746 | <1% | 1,656 | $20K | |
| 97165 | <1% | 153 | $19K | |
| 83735 | <1% | 9,351 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,874 | $18K |
| 83540 | <1% | 1,931 | $18K | |
| 99406 | <1% | 601 | $17K | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 168 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,706 | $17K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 686 | $15K |
| 86140 | <1% | 4,391 | $15K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 293 | $14K |
| 92523 | <1% | 180 | $14K | |
| 73030 | <1% | 486 | $14K | |
| 74018 | <1% | 466 | $13K | |
| 73130 | <1% | 557 | $12K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 105 | $12K |
| 85610 | <1% | 4,693 | $12K | |
| 80320 | <1% | 907 | $12K | |
| 84436 | <1% | 727 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 88 | $11K |
| G0378 | Hospital observation service, per hour | <1% | 218 | $10K |
| 87077 | <1% | 1,447 | $10K | |
| 86617 | <1% | 493 | $10K | |
| 84479 | <1% | 711 | $10K | |
| 73630 | <1% | 579 | $9K | |
| 93971 | <1% | 92 | $9K | |
| 85046 | <1% | 1,219 | $8K | |
| 97113 | <1% | 99 | $8K | |
| 84481 | <1% | 637 | $8K | |
| 86003 | <1% | 179 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 76 | $8K |
| 73562 | <1% | 335 | $7K | |
| 76770 | <1% | 47 | $7K | |
| 87186 | <1% | 1,597 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $7K |
| 73610 | <1% | 514 | $7K | |
| 73110 | <1% | 146 | $7K | |
| 88142 | <1% | 373 | $7K | |
| 72100 | <1% | 305 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 288 | $7K |
| 80074 | <1% | 303 | $6K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,905 | $6K |
| 72110 | <1% | 87 | $6K | |
| 73502 | <1% | 191 | $6K | |
| 85651 | <1% | 1,201 | $6K | |
| 86225 | <1% | 303 | $6K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 108 | $6K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 91 | $6K |
| 97014 | <1% | 154 | $6K | |
| 83690 | <1% | 5,703 | $5K | |
| 71250 | <1% | 55 | $5K | |
| 82785 | <1% | 179 | $5K | |
| 84153 | <1% | 282 | $5K | |
| 97162 | <1% | 62 | $5K | |
| 82570 | <1% | 473 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,688 | $5K |
| 86431 | <1% | 425 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 409 | $5K |
| 80076 | <1% | 349 | $4K | |
| 84550 | <1% | 561 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,650 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 380 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 20 | $4K |
| 82043 | <1% | 535 | $4K | |
| 86038 | <1% | 424 | $4K | |
| 12002 | <1% | 25 | $4K | |
| 12001 | <1% | 28 | $4K | |
| 82140 | <1% | 278 | $4K | |
| 70486 | <1% | 48 | $4K | |
| 92522 | <1% | 41 | $4K | |
| 87481 | <1% | 103 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 293 | $3K |
| 84100 | <1% | 528 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 158 | $3K |
| 84702 | <1% | 881 | $3K | |
| 85730 | <1% | 3,893 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 18 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 147 | $3K |
| 87040 | <1% | 1,674 | $3K | |
| 87420 | <1% | 575 | $3K | |
| 83970 | <1% | 82 | $2K | |
| 82550 | <1% | 886 | $2K | |
| 97168 | <1% | 28 | $2K | |
| 87205 | <1% | 463 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 95 | $2K |
| 97016 | <1% | 77 | $2K | |
| 73560 | <1% | 27 | $2K | |
| 86618 | <1% | 48 | $2K | |
| 90715 | <1% | 142 | $2K | |
| 87081 | <1% | 1,099 | $1K | |
| 87510 | <1% | 46 | $1K | |
| 83880 | <1% | 715 | $1K | |
| 87075 | <1% | 186 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,237 | $1K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 16 | $988.17 |
| 87480 | <1% | 46 | $950.42 | |
| 81025 | <1% | 1,388 | $927.33 | |
| 82248 | <1% | 112 | $914.65 | |
| 72072 | <1% | 15 | $897.72 | |
| 73080 | <1% | 50 | $872.85 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 281 | $837.54 |
| 87625 | <1% | 12 | $804.41 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,082 | $769.49 |
| 85007 | <1% | 633 | $740.84 | |
| 86850 | <1% | 43 | $721.04 | |
| 86328 | <1% | 21 | $696.93 | |
| 86900 | <1% | 43 | $643.61 | |
| J3490 | Unclassified drugs | <1% | 145 | $608.07 |
| 87660 | <1% | 46 | $601.68 | |
| 80164 | <1% | 52 | $582.38 | |
| 73564 | <1% | 15 | $572.46 | |
| 80069 | <1% | 30 | $529.61 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 267 | $478.20 |
| 86762 | <1% | 31 | $461.03 | |
| 86592 | <1% | 80 | $455.13 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 134 | $436.43 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 872 | $372.60 |
| 80329 | <1% | 467 | $371.10 | |
| 80177 | <1% | 29 | $363.20 | |
| 86901 | <1% | 43 | $351.48 | |
| 96376 | <1% | 132 | $350.92 | |
| 84460 | <1% | 30 | $345.76 | |
| 87147 | <1% | 30 | $290.45 | |
| 84703 | <1% | 72 | $265.24 | |
| 84156 | <1% | 49 | $255.02 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 769 | $249.73 |
| 82947 | <1% | 19 | $248.76 | |
| 84134 | <1% | 33 | $239.53 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 314 | $238.56 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,034 | $173.39 |
| 86308 | <1% | 41 | $164.26 | |
| 84402 | <1% | 12 | $162.85 | |
| 84146 | <1% | 14 | $150.47 | |
| 82565 | <1% | 12 | $144.09 | |
| 86703 | <1% | 14 | $132.55 | |
| 85379 | <1% | 127 | $106.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,000 | $105.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 190 | $103.92 |
| 88304 | <1% | 43 | $82.22 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 828 | $79.21 |
| 70320 | <1% | 85 | $79.03 | |
| 88300 | <1% | 53 | $66.36 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 948 | $55.24 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 511 | $52.16 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,074 | $35.30 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 325 | $27.16 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 579 | $24.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 758 | $23.17 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 270 | $14.19 |
| 86701 | <1% | 33 | $13.10 | |
| 86702 | <1% | 33 | $13.10 | |
| J1815 | Injection, insulin, per 5 units | <1% | 16 | $9.45 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 35 | $3.62 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 273 | $2.34 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 47 | $1.31 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 94 | $0.61 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 258 | $0.19 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 25 | $0.00 |
| 94760 | 0% | 70 | $0.00 | |
| 94761 | 0% | 18 | $0.00 | |
| 00126 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.